Merck bets $700M on an antibody drug’s potential in immune diseases

Merck & Co. on Friday acquired an experimental drug designed to wipe out the immune system’s B cells in a deal that adds to a surge of industry interest in using so-called bispecific antibodies to treat autoimmune diseases.